RSV, respiratory syncytial virus, usually peaks in December and January while infecting the nose, throat and lungs, usually ...

During the COVID pandemic, RSV showed a slightly odd pattern: like flu, it basically disappeared in the 2020–2021 season, ...

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

The virus is a common respiratory illness that infects the lungs and airways. Most people experience mild symptoms, like the common cold. However, RSV can cause more severe symptoms in infants, older ...

From today, February 3, pregnant women in Australia will be eligible for a free RSV vaccine under the National Immunisation ...

RSV is a common virus that affects the lungs and breathing passages, and here are some steps you can take to protect yourself ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

More than 86,000 recorded cases of respiratory syncytial virus in 2024 were in children younger than four years old.

US health chiefs issued a warning about RSV jabs, which were only launched in Britain last year.In the UK, the condition is ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary ... period with a higher AUC implying a more intense infection. The trial involved 114 healthy adults who ...

As health officials report a surge of winter viruses, health experts are warning that heart disease symptoms can sometimes ...